EIGR
$9.20
Eiger Biopharma
$.45
5.14%
EIGR
Earnings Whisper ®
N/A
4th Quarter December 2020
Consensus:  $0.03
Revenue:  $0.18 Mil
Thursday
Feb 4
Before the open
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when EIGR reports earnings?
Beat
Meet
Miss

Where is EIGR's stock price going from here?
Up
Flat
Down
Stock chart of EIGR
Analysts
Summary of analysts' recommendations for EIGR
Score
Grade
Pivots
Resistance
$10.05
$9.68
$9.44

$9.07

Support
$8.83
$8.46
$8.22
Tweet
Growth
Description
Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company which develops and manufactures drugs and therapies for the treatment of orphan diseases. Eiger BioPharmaceuticals, Inc., formerly known as Celladon Corporation, is based in Palo Alto, California.